This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Atrial Fibrillation and Flutter심방세동 및 조동

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: I48 (atrial fibrillation and flutter) | Special Copayment Reduction: V192 (special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date)
B. SynonymsParoxysmal AF, Persistent AF, long-standing persistent AF, permanent AF, atrial flutter (AFL), Atypical AFL
C. Adult onsetPrevalence rises sharply with age, reaching about 10–15% in people aged 70 and older. It is 1.5 times more common in men than in women, and hypertension, heart failure, valvular disease and diabetes are the main risk factors.
1. History1906: Einthoven recorded AF by electrocardiogram. Anticoagulation therapy established from the 1960s, innovation in AF ablation in the 2000s, and introduction of the AF-CARE framework in the 2024 ESC guidelines.
2. CausesCauses include hypertension (most common), coronary artery disease, heart failure, valvular disease (mitral valve), hyperthyroidism, obesity, alcohol consumption, postoperative AF and lung disease.
3. GeneticsIn addition to variants in multiple genes such as KCNQ1, KCNE2, SCN5A, GJA5 and PITX2, risk loci discovered by GWAS, such as 4q25, have been identified.
4. General epidemiologyGlobal prevalence is about 2–4%, and about 1.6–2% in Korea. The number of patients is projected to more than double from the current level by 2050.
5. PathophysiologyEctopic firing in the pulmonary veins triggers AF, and AF is sustained by atrial fibrosis, remodeling and maintenance of reentrant circuits. Abnormal calcium handling and autonomic imbalance are also involved.
6. SymptomsPalpitations, dyspnea, fatigue, reduced exercise tolerance, dizziness. About 25–30% are asymptomatic. Stroke or heart failure may be the first presenting symptom.
7. SignsCharacterized by an irregular pulse and, on ECG, absent P waves and irregular RR intervals. In atrial flutter, regular flutter waves at 250–350bpm are seen.
8. ScreeningRegular pulse checks and ECG screening are recommended for people aged 65 and older. Smartwatch/patch ECGs and AF detection built into blood pressure monitors are used.
9. DiagnosisConfirmed by an ECG recording of 30 seconds or longer. Blood tests (thyroid, BNP), echocardiography, Holter monitoring and transesophageal echocardiography (to check for thrombus) are needed.
10. TreatmentAF-CARE framework: management of comorbidities/risk factors, anticoagulation (DOAC), rate control or rhythm control (drugs/ablation), dynamic reassessment. Ablation is a first-line option in paroxysmal AF.
11. PrognosisRisk of stroke increased about 5-fold. Anticoagulation can prevent 60–70% of strokes. Risk of heart failure increased 3-fold in AF without appropriate treatment.
12. PreventionActive management of risk factors (hypertension, obesity, alcohol use, sleep apnea, diabetes), regular aerobic exercise and continued anticoagulant use are key to primary prevention and prevention of complications.
13. References2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS … and 9 other papers

1. History

The history of atrial fibrillation (AF) is closely tied to the development of electrocardiography. In 1906, atrial fibrillation was first recorded by electrocardiogram using the string galvanometer developed by Willem Einthoven, and the concept of "disorderly atrial excitation (delirium cordis)" was proposed. In 1913, Lewis explained AF as multiple irregular reentrant waves in the atrial muscle, and in 1924, Garrey experimentally demonstrated the reentrant mechanism of AF.

The first important advance in treatment was rate control with digoxin in the 1940s–50s. Pharmacological conversion to sinus rhythm with quinidine was then attempted in the 1960s, but long-term success rates were limited. In 1962, Bernard Lown succeeded in electrical cardioversion of atrial fibrillation using direct-current shock. The history of anticoagulation began with the clinical introduction of warfarin in the 1950s, and large randomized controlled trials in the 1990s (AFASAK, SPAF, etc.) proved that warfarin is highly effective in preventing AF-related stroke.

The electrophysiological breakthrough began in 1998 when Haïssaguerre showed that ectopic firing originating in the pulmonary veins triggers AF. Based on this discovery, catheter ablation based on pulmonary vein isolation (PVI) rapidly emerged as a curative treatment for AF. Since the 2000s, 3D electroanatomical mapping, contact-force-sensing catheters and cryoballoon ablation have been introduced, greatly improving the safety and success rate of ablation. In the 2010s, direct oral anticoagulants (DOACs) such as dabigatran, rivaroxaban and apixaban appeared, showing equivalent or better stroke prevention and superior safety without the cumbersome monitoring of warfarin. The ESC guidelines published in 2024 opened a new era by introducing the AF-CARE (Comorbidity, Avoid stroke, Reduce symptoms, Evaluate) framework as an integrated system of AF management.


2. Causes

The causes of atrial fibrillation and flutter are very diverse, and in most cases more than one cause acts in combination. Hypertension is the most common cause of AF, acting as the underlying cause in about 30–40% of all AF patients. Elevated left atrial pressure and atrial fibrosis form the substrate for AF. Coronary artery disease and heart failure cause AF through atrial ischemia and pressure/volume overload. In particular, heart failure and AF form a vicious cycle in which each worsens the other bidirectionally (the AF–heart failure vicious cycle).

Valvular disease, especially mitral stenosis and mitral regurgitation, causes left atrial enlargement and raises the risk of AF. Nonvalvular AF accounts for about 70–80% of all cases. Hyperthyroidism causes AF through sympathetic activation and electrophysiological changes in atrial cells, and AF often resolves once thyroid function is normalized.

Obesity (BMI ≥30) increases the risk of AF by about 50% through increased epicardial adipose tissue, left atrial enlargement and atrial fibrosis, and recent research has shown that weight loss significantly reduces AF burden (LEGACY study). Alcohol consumption causes acute AF ("Holiday heart syndrome") and chronic AF, and abstinence reduces AF recurrence (HOLIDAY study). Lung disease (chronic obstructive pulmonary disease, pulmonary hypertension) and sleep apnea are also important causes. Postoperative AF following cardiac surgery (coronary artery bypass grafting, valve surgery) occurs with a frequency of about 20–40%, mostly 2–4 days after surgery.


3. Genetics

Genetic factors contribute substantially to atrial fibrillation, and genetic predisposition plays a strong role particularly in early-onset (under age 60) AF. A family history is reported to increase the risk of AF about 1.4–1.9-fold. Large genome-wide association studies (GWAS) have discovered more than 30 AF risk loci, the strongest being 4q25 (near the PITX2 gene). PITX2 is a transcription factor that regulates development of the pulmonary veins and left atrium, and its variants are thought to contribute to the triggering of AF originating in the pulmonary veins.

Familial AF due to single-gene variants is rare, but variants in ion channel genes such as KCNQ1 (Kv7.1 potassium channel), KCNE2 (MiRP1), KCNH2 (hERG) and SCN5A (Nav1.5) have been reported. These alter the duration of the atrial action potential and conduction velocity, forming an AF substrate. GJA5 (connexin 40) variants are associated with slowed atrial conduction, and there are also reports linking NPPA (atrial natriuretic peptide precursor) variants to familial AF. Recently, AF risk prediction models using polygenic risk scores (PRS) have been developed, and their potential for clinical application is being studied.


4. General epidemiology

Atrial fibrillation is the most common sustained cardiac arrhythmia worldwide, with an estimated 37.5 million prevalent patients globally. Prevalence in the general population is about 2–4%, rising sharply with age to about 10–15% in those aged 70 and older and about 15–20% in those aged 80 and older. The lifetime risk is very high, at about 25–33% in adults aged 40 and older.

Incidence is about 1.4–1.5 times higher in men than in women, but the sex difference narrows in the elderly population. In Korea, based on Health Insurance Review & Assessment Service (HIRA) data, AF prevalence increased from about 0.7% in 2005 to about 1.6% in 2015, and it is expected to increase further with continued population aging. The annual incidence of stroke in Korean AF patients is reported to be about 3–5%.

The prevalence of atrial flutter (AFL) is lower than that of AF, and interconversion with AF is common. Typical AFL is due to a reentrant circuit around the tricuspid valve (cavotricuspid isthmus-dependent reentry), with a flutter rate of about 250–350/min and a ventricular response usually of about 130–150/min with 2:1 atrioventricular conduction. AF develops concurrently or subsequently in about 50% of patients with AFL.


5. Pathophysiology

The mechanism of atrial fibrillation is broadly divided into two stages: trigger and maintenance. The most important triggering mechanism is ectopic premature beats originating in the pulmonary veins, identified by Haïssaguerre and colleagues in 1998. Cells in the myocardial sleeves at the junction of the pulmonary veins and left atrium have high automaticity and frequently generate premature beats, which trigger multiple reentrant circuits in the atria.

Maintenance mechanisms of AF include the multiple wavelets hypothesis proposed by Moe in 1959, and the hypotheses of stable spiral waves (rotors) and high-frequency drivers. The role of the atrial substrate is very important: atrial fibrosis, atrial enlargement and conduction heterogeneity create an anatomical and electrophysiological environment in which multiple reentrant circuits can be sustained. AF itself alters the atria electrically and structurally, further perpetuating AF — the "AF begets AF" phenomenon.

At the cellular level, rapid atrial excitation during AF (400–700/min) leads to downregulation of L-type calcium channels (ICaL), which shortens the action potential duration and the reentrant wavelength, contributing to the maintenance of AF. In addition, spontaneous calcium release due to phosphorylation of RYR2 causes delayed afterdepolarizations (DADs) and increases ectopic firing. The autonomic nervous system also plays an important role: activation of the intracardiac ganglionated plexi contributes to the initiation and maintenance of AF.

The mechanism of atrial flutter differs from that of AF. Typical AFL is due to a macro-reentrant circuit in the right atrium that includes the tricuspid annulus, inferior vena cava, Eustachian ridge and the isthmus between them and the coronary sinus (cavotricuspid isthmus, CTI). CTI ablation, which interrupts this circuit, is the curative treatment for AFL.


6. Symptoms

Symptoms of atrial fibrillation vary greatly between individuals. The most common symptom is palpitation due to an irregular, rapid heartbeat, reported in about 50–70% of AF patients. Patients usually describe it as "the pulse beating irregularly or skipping," and paroxysmal AF is characterized by sudden onset and termination.

Dyspnea occurs in about 25–40%, reflecting in particular reduced diastolic filling time and decreased cardiac output due to a rapid ventricular rate. Fatigue and reduced exercise tolerance are also common, with a rapid, irregular heartbeat becoming prominent during daily activities or exercise. Dizziness and, rarely, syncope may occur. About 25–30% of AF patients are asymptomatic (silent AF), and in some cases stroke or heart failure is the first presenting symptom.

The European Society of Cardiology (ESC) classifies the severity of AF symptoms using the EHRA (European Heart Rhythm Association) score: EHRA I (no symptoms), EHRA IIa (mild, no limitation of daily activities), EHRA IIb (moderate, daily activities not free of discomfort), EHRA III (severe, daily activities limited), EHRA IV (disabling, all activity impossible).


7. Signs

The most characteristic physical examination finding in atrial fibrillation is an irregularly irregular pulse. The pulse is palpated at the radial or carotid artery at completely irregular intervals, with no regular pattern at all. A pulse deficit — an apical heart rate higher than the radial pulse rate — may be observed at rapid heart rates. This reflects beats after a short diastole that fail to generate sufficient stroke volume, so the peripheral pulse wave is not transmitted.

On cardiac auscultation, irregular intervals between heart sounds and variation in their intensity are observed; with loss of the P wave, the intensity of the first heart sound (S1) varies from beat to beat. If mitral valve disease is present, the corresponding valvular murmur is heard. In atrial flutter, the pulse is usually regular (heart rate about 150/min with 2:1 atrioventricular conduction), and coarse, regular flutter waves (sawtooth pattern) in lead V1 on ECG are characteristic. If heart failure is present, elevated jugular venous pressure, pulmonary crackles and lower-limb edema accompany it.


8. Screening

Opportunistic screening for early detection of asymptomatic AF is carried out in adults aged 65 and older through pulse palpation and ECG recording. If an irregular rhythm is found, an immediate 12-lead ECG is needed. The 2024 ESC guidelines recommend systematic screening using single-lead ECG recording devices (smartwatches, patch ECGs) in people aged 65 and older or in high-risk groups (hypertension, diabetes, heart failure, history of stroke).

Advances in smartwatches and wearable ECG devices have made long-term, continuous AF monitoring possible. The sensitivity of Apple Watch-based AF detection is reported to be about 72–85%, with a specificity of about 99%. After a stroke, long-term Holter monitoring or an ILR is actively used to search for subclinical AF. AF detection built into blood pressure monitors (Omron, etc.) automatically detects an irregular pulse during home blood pressure measurement, contributing to AF screening.


9. Diagnosis

Confirmation of atrial fibrillation requires absent P waves and irregular RR intervals on an ECG recording of 30 seconds or longer. The ECG is the standard for AF diagnosis. ECG findings of AF: (1) irregular baseline undulation without distinguishable P waves (fibrillatory baseline), (2) completely irregular RR intervals, (3) normal QRS complexes (in the absence of intraventricular conduction abnormalities). ECG findings of atrial flutter: regular sawtooth flutter waves at 250–350/min (negative in leads II, III and aVF) are characteristic.

After diagnosis, the following tests are performed to evaluate the cause: blood tests (thyroid function tests, electrolytes, renal function, liver function, blood count, blood glucose, coagulation tests), echocardiography (assessment of atrial size, ventricular function and valvular abnormalities) and chest X-ray (cardiomegaly, pulmonary congestion). Before starting anticoagulation or before cardioversion, transesophageal echocardiography (TEE) should be used to check for thrombus in the left atrial appendage. Following EHRA criteria, the CHA2DS2-VA score is calculated to determine the indication for anticoagulation (anticoagulation recommended at a score of 1 or more in men and 2 or more in women).


10. Treatment

The 2024 ESC guidelines integrate AF management into the AF-CARE framework: [C] management of comorbidities and risk factors, [A] prevention of stroke and thromboembolism, [R] rate/rhythm control, [E] evaluation and dynamic reassessment.

Anticoagulation is the most important element of AF management. Anticoagulation is recommended when the CHA2DS2-VA score is ≥1 (men) or ≥2 (women), and in nonvalvular AF, DOACs (dabigatran, rivaroxaban, apixaban, edoxaban) are recommended in preference to warfarin. DOACs are equivalent or superior to warfarin in stroke prevention while carrying a significantly lower risk of intracranial hemorrhage. Left atrial appendage (LAA) occlusion devices (WATCHMAN, etc.) are an alternative for patients who cannot take long-term anticoagulation.

Rate control targets a resting heart rate of <110/min (lenient rate control), using beta-blockers, non-dihydropyridine calcium channel blockers and digoxin. Rhythm control is performed to improve symptoms and preserve cardiac function, and the EAST-AFNET 4 study published in 2020 showed that early rhythm control (within 1 year of diagnosis) improves cardiovascular outcomes. In the 2024 ESC guidelines, catheter ablation (pulmonary vein isolation) is recommended as a Class I first-line treatment option for paroxysmal AF and AF with suspected tachycardia-induced cardiomyopathy.


11. Prognosis

If not appropriately treated, atrial fibrillation leads to many serious complications. Stroke is the most serious complication of AF; the risk of ischemic stroke in AF patients is about 4–5 times higher than in people without AF. AF-related strokes in particular are larger and more severe than strokes of other causes, with a 30-day mortality of about 25%. Anticoagulation can reduce the risk of stroke by about 60–70%.

The risk of developing heart failure is increased about 3-fold in AF patients, and AF and heart failure form a vicious cycle in which each worsens the other. If a rapid heart rate persists, tachycardia-mediated cardiomyopathy develops, and cardiac function may recover with rate control or conversion to sinus rhythm. AF increases the overall risk of death about 1.5–2-fold and is an independent predictor of cardiovascular death in particular. The rate of sinus rhythm maintenance after catheter ablation is about 65–75% at 1 year after a single procedure, improving to over 80% with repeat procedures.


12. Prevention

Primary prevention of atrial fibrillation focuses on active management of risk factors. Treatment of hypertension is one of the most effective ways to prevent AF; keeping systolic blood pressure below 130mmHg significantly lowers the risk of developing AF. Weight management is highly effective in preventing AF and suppressing recurrence. The LEGACY study showed that losing 10% or more of body weight reduces the AF recurrence rate by about half.

Reducing alcohol intake is also important; reducing consumption (≤7 units/week) significantly lowers the AF recurrence rate (HOLIDAY study). Treatment of sleep apnea (CPAP) reduces AF recurrence and is particularly effective in preventing recurrence after catheter ablation. Regular moderate aerobic exercise (150 minutes or more per week) reduces the risk of AF, but extreme exercise (long-distance running, cycling) may actually increase it. Diabetes control, smoking cessation and treatment of dyslipidemia also contribute to lowering AF risk. In patients already diagnosed with AF, continued anticoagulant use and risk factor management are key to preventing complications.


13. References

  1. Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-3414. DOI: 10.1093/eurheartj/ehae176. PMID: 39210723.

  2. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021;42(5):373-498. DOI: 10.1093/eurheartj/ehaa612. PMID: 32860505.

  3. Kirchhof P, Camm AJ, Goette A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020;383(14):1305-1316. DOI: 10.1056/NEJMoa2019422. PMID: 32865375.

  4. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011;365(11):981-992. DOI: 10.1056/NEJMoa1107039. PMID: 21870978.

  5. Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659-666. DOI: 10.1056/NEJM199809033391003. PMID: 9725923.

  6. Pathak RK, Middeldorp ME, Meredith M, et al. Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY). J Am Coll Cardiol. 2015;65(20):2159-2169. DOI: 10.1016/j.jacc.2015.03.002. PMID: 25975469.

  7. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14(10):e275-e444. DOI: 10.1016/j.hrthm.2017.05.012. PMID: 28506916.

  8. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119-125. DOI: 10.1161/CIRCULATIONAHA.105.595140. PMID: 16818816.

  9. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-988. DOI: 10.1161/01.str.22.8.983. PMID: 1866765.

  10. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009;361(12):1139-1151. DOI: 10.1056/NEJMoa0905561. PMID: 19717844.